Grupo de Investigación en Neuropsicofarmacología

• Almodóvar-Payá C, Guardiola-Ripoll M, Giralt-López M, Gallego C, Salgado- Pineda P, Miret S, Salvador R, Muñoz MJ, Lázaro L, Guerrero-Pedraza A, Parellada M, Carrión MI, Cuesta MJ, Maristany T, Sarró S, Fañanás L, Callado LF, Arias B, Pomarol-Clotet E, Fatjó-Vilas M.  NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches International Journal of Molecular Sciences,  2022;  23(13):7456
• Casaletto K, Ramos-Miguel A, VandeBunte A, Memel M, Buchman A, Bennett D,Honer W.  Late-life physical activity relates to brain tissue synaptic integrity markers in older adults Alzheimers Dement,  2022;  8(11),  2023 - 2035
• Erkizia-Santamaría I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE.  Serotonin 5-HT2A, 5-HT2C and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response Biomedicine & Pharmacotherapy,  2022;  154:113612
• Ibarra-Lecue I, Unzueta-Larrinaga P, Barrena-Barbadillo R, Villate A, Horrillo I, Mendivil B, Landabaso MA., Meana JJ, Etxebarria N, Callado LF, Urigüen L.  Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients Addiction Biology,  2022;  27(6):e13233
• Navinés R, Oriolo G, Horrillo I, Cavero M, Aouizerate B, Schaefer M, Capuron L, Meana JJ, Martin-Santos R.  High S100B levels predict antidepressant responsein patients with major depression even when considering inflammatory and metabolic markers Journal of Neuropsychopharmacology,  2022;  25(6),  468 - 478
• Saunders JM, Muguruza C, Sierra S, Moreno JL, Callado LF, Meana JJ, Beardsley PM, González-Maeso J.  Glucocorticoid receptor dysregulation underlies 5-HT 2A R-dependent synaptic and behavioral deficits in a mouse neurodevelopmental disorder model Journal of Biological Chemistry,  2022;  298(11):102481